The XIENCE Skypoint™ 48 mm Stent is designed so that interventional cardiologists (ICs) can use only one stent in long coronary lesions. Diffuse coronary disease—with long lesions—can otherwise be challenging when employing multiple stents.2
There are several advantages in using a single long stent vs several shorter stents in percutaneous coronary intervention (PCI):
Use of a single longer stent, vs 2 shorter stents, also reduces overlap. In fact, stent overlap has been reported in as many as 30% of patients undergoing PCI. Overlapping stents may also result in:
XIENCE Skypoint™ Stent also offers a 4.0 x 48mm stent size to help treat larger vessels where there may be diffuse disease.
Long XIENCE™ Stents continue the tradition of excellent XIENCE™ safety outcomes. XIENCE™ 48 mm Stents demonstrate impressive outcomes in long lesions:
Data from XIENCE Prime™ Stent & XIENCE Xpedition™ Stent
When using XIENCE™ 48 mm Stents in long, complex lesions, there were low rates of myocardial infarction (MI), TLR, and major adverse cardiac events (MACE) 1 year after the index procedure. In this analysis the mean stented length was 58 mm.
Additional data supported the safety of XIENCE™ Stent in long lesions, with findings displaying consistent performance between moderate length lesions and long lesions.
|Moderate Length Lesions|
(> 24 mm to < 35 mm)
|Long Length Lesions|
(> 35 mm)
|TLF at 1 Year||10%||8.9%||p = 0.63|
|Mean Lesion Length||28.1 mm||47.1 mm||p < 0.0001|
The 5-year data from the IVUS-XPL study reveal excellent XIENCE™ Stent outcomes in long lesion treatment guided by intravascular ultrasound (IVUS). Study results show low event rates with long lesions treated with long stents.
Note the low rates of both definite or probable ST (0.3%) and MACE (5.6%).
† XIENCE™ Stent safety outcomes include data on XIENCE Prime™ Stent & XIENCE Xpedition™ Stent.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions